Innovative diagnostic and eHealth monitoring system for diabetic foot complications

Projektinformationen

FeetWell

ID Finanzhilfevereinbarung: 773312

DOI

10.3030/773312

Projekt abgeschlossen

EK-Unterschriftsdatum 12 Mai 2017

Startdatum 1 Mai 2017

Enddatum 31 August 2017

Finanziert unter

• SOCIETAL CHALLENGES - Health, demographic change and well-being

Gesamtkosten

€ 71 429,00

EU-Beitrag

€ 50 000,00

Koordiniert durch

UAB METIS BALTIC
Lithuania

Periodic Reporting for period 1 - FeetWell (Innovative diagnostic and eHealth monitoring system for diabetic foot complications)

Berichtszeitraum: 2017-05-01 bis 2017-08-31

Zusammenfassung vom Kontext und den Gesamtzielen des Projekts

FEETWELL™ is a non-invasive diagnostic device aimed at the early detection and prevention of Diabetic Foot Complications. FEETWELL™ incorporates a novel eHealth software solution with intuitive interfaces that does not require highly skilled personnel for its operation and can scan the entire foot area in less than 30 minutes. Moreover, it is the only device for this purpose that provides qualitative and quantitative data of the integrity of the foot tissue in diabetes patients. During this project, we will design two FEETWELL™ systems for two types of end users: one for health practitioners, for early diagnosis and monitoring of the DFU risk (FEETWELL™ PRO) and one for patient use (FEETWELL™ BASIC) to indicate the patient when to visit the doctor.

Arbeit, die ab Beginn des Projekts bis zum Ende des durch den Bericht erfassten Berichtszeitraums geleistet wurde, und die wichtigsten bis dahin erzielten Ergebnisse

We have performed a Feasibility study during 4 months, focused on the technical, commercial and financial requirements of our FEETWELL™ technology. For the technical feasibility study, we have interviewed potential users (primary care doctors and podiatrists) to identify the key requirements for a diagnostic system like FEETWELL™ and with this information we have defined the minimum key product specifications for both systems (FEETWELL™ PRO, and FEETWELL™ BASIC). We have also identified the technical updates for FEETWELL™ Industrial versions. And finally, we have prepared a complete Execution Plan that includes planning, organization, risk analysis and budget. For the commercial feasibility analysis, we have assessed the targeted markets and competitors to prepare our go-to market strategy. We have also performed an IPR assessment through a Freedom-to-Operate analysis, confirming that we can freely operate in our target regions. We have also defined an IPR Strategy for FEETWELL™ technology.

Fortschritte, die über den aktuellen Stand der Technik hinausgehen und voraussichtliche potenzielle Auswirkungen (einschließlich der bis dato erzielten sozioökonomischen Auswirkungen und weiter gefassten gesellschaftlichen Auswirkungen des Projekts)

The main users of FEETWELLTM will be doctors and nurses who provide care for DM patients and monitor their health parameters, and thus our main customers will be the medical offices (state hospitals, local surgeries, private clinics, consulting rooms, sanatoria) where these users develop their activity.
These users (and thus our customers) are in need for tools that facilitate routine diagnosis of DFUs.
Our system can reduce the economic burden of foot diabetes complications in 50% and improve the quality life of the patients reducing the depression and loss of productivity due the incidence of foot ulcers and limb amputations thanks to the early detection of the DFU risks with FEETWELL systems.

iimage-1.png